Press
-
20 February 2026
Klaria Year-End Report
Klaria Year-End Report Q4 2025 1 January–31 December 2025
-
23 December 2025
Klaria accelerates its business development work in collaboration with BDO
With Klaria’s product, Sumatriptan Alginate Film, approved in the EU and set to launch in 2026 in the largest EU markets, the company has now engaged BDO LLP’s UK Life Sciences & Healthcare M&A team (‘BDO’) to support business development initiatives in strategically important markets. In line with this, several strategic options are being considered that may lead to different potential outcomes, all with the aim of maximizing shareholder value.
-
17 December 2025
Klaria Receives Positive Opinion on Sumatriptan Oral Film Patent Application
Klaria announced earlier in the year that it had submitted an additional patent application on the sumatriptan oral film product to further protect the product and potentially extend its market exclusivity. The International Search Authority (ISA), which informs the decisions of the European Patent Office (EPO) as well as many other international patent authorities has issued their report stating that all claims made in the application fulfill all requirements of patentability.
-
26 November 2025
Klaria Interim Report Q3 2025
Klaria Interim Report 1 July – 30 September 2025
-
28 August 2025
Klaria Interim Report Q2 2025
Klaria interim report 1 April–30 June 2025
-
03 July 2025
Klaria stengthens patent portfolio of sumatriptan alginate film with new filing
Klaria AB has filed a ‘third generation’ patent application to protect the sumatriptan alginate film product. The current application, when granted, would give the product worldwide market exclusivity to 2045.
-
21 May 2025
Klaria Interim Report
Klaria interim report 1 January–31 March 2025
-
30 April 2025
Klaria Annual Report 2024
Klaria Pharma Holding AB Annual Report 2024
-
28 February 2025
Klaria Year-End Report 2024
Klaria year-end report 1 Jan - 31 Dec 2024
-
10 January 2025
Klaria signs license agreement for Sumatriptan Alginate film in Europe with CNX Therapeutics
Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that the Company has signed a license agreement for Sumatriptan Alginate Film (the "Product"), a pharmaceutical product based on Klaria's patented alginate films for fast and reliable administration via the oral mucosa, which is approved in Germany, Spain and Italy for the treatment of migraine with or without aura, with CNX Therapeutics Limited (“CNX Therapeutics”). The agreement gives CNX Therapeutics the right to market and sell the Product in Europe and the UK under its own brand and product name, and the parties plan an initial launch in Germany, Spain and Italy in the second half of 2025 with further expansion in 2026. The agreement gives Klaria an up-front payment of EUR750,000, milestone payments of approx. EUR500,000 – 1,250,00 based on pricing per geographic market for the first 8 countries, as well as a double-digit royalty based on sales revenue. Furthermore, negotiable milestone payments are possible when expanding the market territory within the EEA. In addition to the license agreement, Klaria has a long-term business relationship with AdhexPharma SAS, a leading CDMO located in France and Germany, as the parties’ production partner. Today, AdhexPharma has an annual production capacity of 200 million units, with plans to scale up to meet market demand for Sumatriptan Alginate Film.
-
21 November 2024
Klaria Interim Report Q3 2024
Klaria Interim Report Q3 2024 1 July - 30 September 2024
-
22 August 2024
Klaria Interim Report Q2 2024
Summary of Interim Report
-
14 August 2024
Klaria Sumatriptan Alginate Film Receives Marketing Authorization
Klaria has been notified by the German Federal Institute for Drug and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) that the review process has concluded, and that marketing authorization for the treatment of migraine with and without aura is granted.
-
16 May 2024
Klaria Interim Report Q1 2024
1 January - 31March 2024
-
29 February 2024
Klaria Year-End Report 2023
Summary of the interim report
-
26 February 2024
Klaria accelerates its business development efforts
With Klaria’s Sumatriptan Alginate Film product in approval process Klaria is now accelerating its business development efforts and has engaged Ernst & Young AB Corporate Finance (EY) to identify potential strategic partnerships for its assets. In line with this, several options are being considered that could lead to different potential outcomes, with the objective to maximize shareholder value.
-
24 November 2023
Klaria Interim Report Q3 2023
1 July - 30 September 2023
-
25 October 2023
Klaria’s board of directors announces that CEO Jesper Wiklund leaves the company
The board of Klaria Pharma Holding AB (publ) announces that Jesper Wiklund is leaving the CEO position to focus on other activities based in Germany. Fredrik Hübinette, the company’s chairman of the board, will assume the position as acting CEO with immediate effect during a transition period.
-
25 August 2023
Klaria Interim Report
Q2 2023 1 April - 30 June
-
12 May 2023
Klaria Interim Report Q1 2023
